Answers are grounded in this paper and cite their sources.
Monoclonal gammopathy of renal significance (MGRS) is a pathogenic entity associated with significant morbidity, mainly end stage kidney disease. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID), a type of MGRS, is a specific disease resulting from the deposition of a monoclonal immunoglobulin leading to kidney damage. While PGNMID has been recognized to lead to end-stage kidney disease, until recently there was no evidence to guide treatment. Here, we report a case of a patient with PGNMID who responded well to daratumumab.
No takes yet. Share an insight, caveat, or question.
Doddi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: